Last reviewed · How we verify
NCT04679428
Immunological Characteristics of COVID-19 Patients
trial in Covid19 in 230 participants. Status unknown.
7 May 2022
Quick facts
| Lead sponsor | The University Clinic of Pulmonary and Allergic Diseases Golnik |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 230 |
| Start date | 7 May 2020 |
| Primary completion | 7 May 2022 |
| Estimated completion | 7 May 2023 |
| Sites | 1 location across Slovenia |
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
The University Clinic of Pulmonary and Allergic Diseases Golnik
Who can join
18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will look at the immunological characteristics of COVID-19 patients and determine neutralizing antibodies against SARS-CoV-2 virus.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunophenotypes of anti-SARS-CoV-2 responses associated with fatal COVID-19.
Šelb J, Bitežnik B, Bidovec Stojković U, Rituper B, et al · · 2022 · cited 1× · PMID 36474964 · DOI 10.1183/23120541.00216-2022 -
Genomic Landscape of Susceptibility to Severe COVID-19 in the Slovenian Population.
Kovanda A, Lukežič T, Maver A, Vokač Križaj H, et al · · 2024 · PMID 39062917 · DOI 10.3390/ijms25147674
Verify or expand the search:
- PubMed search for NCT04679428
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other The University Clinic of Pulmonary and Allergic Diseases Golnik trials
Trials by the same sponsor.
- NCT06637280 — High - Flow Nasal Cannula Versus Conventional Nasal Cannula During Endobronchial Ultrasound Procedure · NA · recruiting
- NCT05907577 — Early Detection of Lung Cancer With Machine Learning Based on Routine Clinical Investigations · unknown
- NCT04716088 — Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19 · completed
- NCT06207500 — Evaluation of Pharmacist-led Medication Reconciliation Service Benefits in Hospitalised Medical Patients · NA · terminated
- NCT04709614 — Psychological Factors That Influence Severity of Allergic Rhinitis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04679428 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University Clinic of Pulmonary and Allergic Diseases Golnik
- Last refreshed: 22 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04679428.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing